Press Releases

CRISPR/Cas9 platform, the mature division of Creative Biogene, is a global leading biotechnology company specializing in gene editing and has extensive experience and expertise in embryology, genetic testing and breeding. With the latest CRISPR/Cas9 gene editing technology, the professional team has revolutionized the way to create animal disease models and study the effects of certain genes on the mouse genome. Recently, Creative Biogene announced the release of its accurate gene knockout mouse models which can be applied to immunology research and drug discovery, as well as preclinical safety and toxicity studies.

Researchers at Creative Biogene have successfully achieved efficient CRISPR/Cas9 gene editing (>98%) in a variety of animals including mice, rats, rabbits, zebrafish, Drosophila, etc. All models have been validated at the genomic level by PCR and sequencing using carefully designed PCR primers around the target site or insert.

Creative Biogene provides high-quality, validated knockout mouse models for generating consistent research data, enabling research reproducibility, and reducing overall research costs. The end-to-end commitment ensures adherence to project timelines, confidentiality, the exclusivity of intellectual property, breeding to VAF Plus standards, and global delivery.

Creative Biogene assists researchers in using gene-edited mouse models to study gene expression, study genetic diseases, conduct preclinical drug efficacy testing, and more. The application of animal models developed using CRISPR technology is relevant to accurately mimic human disease in other mammals, primarily mice. Because of the impact of somatic mutations on cancer development and progression, conditional knockout mouse models can be used to study cancer.

Conditional knockout mice are typically generated using Cre-LoxP, Dre-Rox, or Flp-Frt recombination systems for permanent genetic changes in specific tissues. Creative Biogene primarily bred Floxed mice with tissue-specific Cre or CreERT2 mice, and sequences between LoxP sites would be spatially and/or temporally removed from the genomes of offspring.

“Our CRISPR technology efficiently retargets existing animal models and repositories, potentially reducing animal usage, and generating custom gene knockouts and point mutations at significantly lower costs.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “Our innovative gene editing technology increases gene editing efficiency by 10 to 20 times, enabling our custom model development process faster and more affordable.”

About Creative Biogene

Creative Biogene, as a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.